Skip to main content

Table 2 Effect of electron transport chain complex inhibitors on OCR and ECAR in PBMCs

From: Systemic Immuno-metabolic alterations in chronic obstructive pulmonary disease (COPD)

  

HNS

HS

TS-COPD

Glucose OCR

ATP Production (%)

61.3 (56.5–66.2)

50.7 (48.6–59.6)*

54.8 (48.8–57.3)**

Max Resp. Capacity (%)

91.9 (73.8–109.5)

80.2 (51.6–93.8)

72.1 (59.0–75.7)*

Spare Resp. Capacity (%)

87.5 (61.6–105.4)

57.1 (42.7–69.0)**

68.0 (57.8–77.3)*

Glucose ECAR

Glycolytic Capacity (%)

315.6 (278.7–358.1)

194 (170–267.8)

198.2 (144.4–219.1) *

Glycolytic Reserve (%)

92.4 (65.8–102.6)

84.3 (72.2–110.6)

57.8 (49.7–64.5)*,##

Non-Glycolytic Acidification (%)

73 (63.4–80.3)

74.5 (65.7–92)

94.4 (83.9–99.9)**

Palmitate OCR

ATP Production (%)

53.5 (47.9–72.4)

62.5 (52.7–75.9)

37.7 (31.4–45.8)***, ##

Max Resp. Capacity (%)

101.6 (94.3–118.9)

104.2 (98.3–130.7)

83.1 (56.3–86.5)**, ##

Spare Resp. Capacity (%)

66.7 (47.6–81.1)

65.3 (61.5–95.6)

38.5 (32.4–57.1)*, #

Non-fatty acid Mitochondrial Resp. (%)

30.8 (19.5–42.3)

38.6 (30.6–49.5)

37.4 (25.6–54.8)

  1. Data for ATP production, maximum respiratory capacity, spare respiratory capacity, glycolytic capacity and glycolytic reserve is represented as median % change in OCR/ECAR (Inter-quartile range). Non-glycolytic acidification and non-mitochondrial respiration is represented as percentage of baseline (before adding glucose or palmitate) ECAR and OCR, respectively. HNS Healthy non-smokers, HS Healthy smokers and TS-COPD Tobacco-smoking COPD subjects. * indicates p < 0.05, ** indicates p < 0.01 and *** indicates p < 0.001 as compared to HNS whereas, # indicates p < 0.05 and ## indicates p < 0.01 as compared to HS using the Mann-Whitney U test for between-group comparison